<DOC>
	<DOCNO>NCT02662634</DOCNO>
	<brief_summary>Feasibility Safety study autologous dendritic cell immunotherapy ( AGS-003-LNG ) patient resectable non-small cell lung cancer .</brief_summary>
	<brief_title>A Safety Feasibility Study AGS-003-LNG Treatment Stage 3 Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Feasibility Safety study autologous dendritic cell immunotherapy ( AGS-003-LNG ) patient resectable non-small cell lung cancer . Non-small cell lung cancer tumor resect patient . RNA tumor amplify subsequently electroporated mature , autologous dendritic cell . The dendritic cell tumor RNA dose back patient . Study investigate feasibility safety .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Age ≥ 19 year . 2 . Newly diagnose nonsmall cell lung cancer indicate routine lobectomy , mediastinoscopy , wedge resection , thoracotomy Videoassisted thoracoscopic surgery ( VATS ) procedures tumor collection . 3 . Stage III ( T13 , N12 , M0 ) histology . 4 . Scheduled routine lobectomy , mediastinoscopy , wedge resection , thoracotomy VATS procedure . 5 . Signed date informed consent document study participation . After tumor collection , potential subject must meet follow criterion enrol study treatment : 1 . Successful RNA isolation amplification tumor sample ( determined Argos ) . 2 . Karnofsky performance status ( KPS ) score 80100 . 3 . Life expectancy six month great . 4 . NSCLC histology . 5 . Resolution acute toxic effect prior radiotherapy surgical procedure Grade ≤ 1 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 . 6 . Negative serum pregnancy test female subject reproductive potential , agreement male female subject reproductive potential use reliable form contraception study 12 week last dose study drug . 7 . Able abstain take prohibit drug , either prescription nonprescription , treatment phase study . 8 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 9 . Signed date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . 1 . Active autoimmune disease condition require chronic immunosuppressive therapy 2 . Any clinically significant condition prohibits initiation standard care . 3 . Malignancies within prior three year , except : treated situ carcinoma nonmelanoma skin cancer . adequately treat early stage breast cancer . superficial bladder cancer . nonmetastatic prostate cancer normal prostatespecific antigen ( PSA ) level . 4 . History known brain metastasis , spinal cord compression , carcinomatous meningitis , evidence brain leptomeningeal disease . 5 . Clinically significant disorder condition include cardiovascular system . renal system . hepatic organ system . coagulation disorder . 6 . Clinically significant infection , include human immunodeficiency virus ( HIV ) , syphilis , active hepatitis B C. 7 . Pregnant breastfeeding . 8 . Any serious medical condition illness consider investigator constitute unwarranted high risk investigational treatment .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>resectable</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>autologous</keyword>
	<keyword>dendritic cell</keyword>
</DOC>